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Abstract
Background: SIFD (Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay)
is a novel form of congenital sideroblastic anemia associated with B-cell immunodeficiency, periodic fevers, and
developmental delay caused by mutations in the CCA-adding enzyme TRNT1, but the precise molecular
pathophysiology is not known.
Results: We show that the disease causing mutations in patient-derived fibroblasts do not affect subcellular
localization of TRNT1 and show no gross morphological differences when compared to control cells. Analysis of
cellular respiration and oxidative phosphorylation (OXPHOS) complexes demonstrates that both basal and maximal
respiration rates are decreased in patient cells, which may be attributed to an observed decrease in the abundance
of select proteins of the OXPHOS complexes.
Conclusions: Our data provides further insight into cellular pathophysiology of SIFD.
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Background
The tRNA nucleotidyl transferase (TRNT1) gene encodes
a protein involved in the maturation of all cytosolic and
mitochondrial tRNAs. It functions to add CCA to the 3’
terminus of tRNA molecules and is required for proper
aminoacylation of all tRNAs [1]. We recently described a
cohort of patients with congenital sideroblastic anemia
with B-cell immunodeficiency, periodic fevers and devel-
opmental delay (SIFD) [2] due to mutations in TRNT1.
We demonstrated that patient mutations result in an
impairment of TRNT1 to catalyze the addition of CCA to
tRNA, while the knockdown of TRNT1 results in
significant cytotoxicity and apoptosis. It was shown subse-
quently that mutations in TRNT1 correlate with the
incomplete addition of CCA to the mitochondrial serine-
tRNA (AGY;[3]), a tRNA possessing a non-canonical
structure [4]. SIFD belongs to a group of congenital
sideroblastic anemias (CSAs) that are characterized by iron
deposits in the mitochondria of red blood cell precursors.
Given that all CSA-associated genes identified to date are
involved in mitochondrial pathways [5], and the critical
role that TRNT1 plays in mitochondrial tRNA maturation,




Control fibroblasts were obtained from Coriell Institute
(Control 1, Cat# GM08680; Control 2, Cat# GM00498)
and from a healthy female donor (Control 3). Patient fibro-
blasts were previously described; patient 7 is compound
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heterozygous TRNT1 p.L166S, p.T154I, whereas patient 8
is homozygous for the TRNT1 p.R190I mutation [2]. Cells
were maintained in Dulbecco's modified Eagle's medium
(DMEM, Thermo Scientific) supplemented with heat-
inactivated 10 % fetal calf serum, 2 mM L-glutamine, and
1 % antibiotics (100 units/ml penicillin–streptomycin) at
37 °C and 5 % CO2.
Cytoplasmic translation assay
Metabolic labeling was done as previously described [6].
Briefly, control and patient-derived fibroblasts were grown
in 6-well plates, washed twice in 1 mL of DMEM lacking
methionine and cysteine (DMEM-Met,Cys) supplemented
with 10 % fetal calf serum and 2 mM L-glutamine and
incubated in 1 mL of DMEM-Met,Cys for 15 minutes at
37 °C and 5 % CO2. 1 mL of 100 μCi
35S-Met, Cys (Perkin
Elmer; NEG772) was added and the cells were incubated
for an additional 25 minutes at 37 °C. Cells were washed
three times in cold PBS (300 x g/5 min/4 °C) and lysed in
RIPA (50 mM Tris [pH7.4], 150 mM NaCl, 1 mM EDTA,
0.25 % sodium deoxycholate, 1 % Igepal, protease inhibi-
tors) buffer. Total protein content was quantified by Brad-
ford protein assay (BioRad) and equal amounts of proteins
were separated by 10 % SDS-PAGE, stained with Coomas-
sie R-250 dye, and exposed to X-ray film.
Western blotting
Cells were washed in 1 mL of PBS and lysed in 150 μL
of RIPA buffer for 30 minutes at 4 °C, followed by cen-
trifugation at 12,000 x g for 10 minutes to pellet debris.
Protein concentrations were determined by Bradford
protein assay, and equal amounts of protein extract were
separated by 10 % SDS-PAGE and transferred to PVDF
membrane. Proteins were identified using anti-OXPHOS
Human cocktail (Abcam; ab110411), anti-Tom20 (Santa
Cruz Biotechnology; sc-11415), anti-TRNT1 (Novus Bio-
logicals; NBPI-86589) or anti-Tubulin (Abcam; ab7291)
followed by species-specific HRP-conjugated secondary
antibodies (Cell Signaling Technology). Antibody com-
plexes were detected using an ECL system (GE Biosci-
ences) and the densitometry analyses were performed
using the ImageJ software.
Immunofluorescence
Fibroblasts were cultured on coverslips or in 384-well plates
(BD Falcon) for 24 hours in DMEM. Cells were fixed with
3.7 % formaldehyde at room temperature for 15 minutes,
washed twice with PBS, and permeabilized for 15 minutes
with 0.1 % Triton X-100 (Sigma) in PBS. Cells were blocked
with 3 % bovine serum albumin (Invitrogen) for 30 minutes
and then incubated overnight at 4 °C with rabbit anti-
TRNT1 primary antibody (Novus Biologicals) diluted 1/50
in PBS buffer containing 2 % BSA and 0.004 % Triton X-
100, or mouse anti-TOM20 primary antibody diluted 1/500.
Cells were washed and incubated with AlexaFluor-488 anti-
rabbit or AlexaFluor-594 anti-mouse antibodies for 1 hour
at room temperature. Nuclei were stained with 2 μg/mL
Hoechst 33342 (Sigma). Cells were imaged using the Olym-
pus Fluoview FV-1000 Laser Confocal Microscope or using
the Opera Imaging system and analyzed using the Colum-
bus Image Analysis Software and Acapella image analysis
scripting language (Perkin Elmer).
Mitochondrial membrane potential staining
Measurement of mitochondrial membrane potential was de-
termined using the potential-sensitive dye Tetramethylrho-
damine ethyl ester perchlorate (TMRE; Molecular Probes).
Briefly, 2000-3000 cells were cultured in a 384-well micro-
plate for 48 hours then incubated for 30 minutes in DMEM
containing 20 nM MitoTracker Green FM (Molecular
Probes). The cells were pre-incubated with 20 μM Carbonyl
cyanide m-chlorophenyl hydrazone (CCCP; to eliminate
mitochondrial membrane potential) or solvent control at
37 °C for 1 hour prior to adding TMRE. After washing with
media, 25 nM TMRE in media containing 0.5 μg/mL
Hoechst 33342 (Molecular Probes) was added to the cells
and incubated for 1 hour at 37 °C. TMRE and MitoTracker
Green fluorescence intensities of the mitochondria in live
cells were imaged using the Opera automated confocal
microscope and analyzed with the Columbus Image Ana-
lysis Software (Perkin Elmer).
Micro-oximetry analysis
Oxygen consumption rate (OCR) was measured using the
XF24 Extracellular Flux Analyzer (Seahorse Bioscience).
Control and patient fibroblasts were seeded in XF 24-well
cell culture microplates at 4 x104 cells/well and incubated
at 37 °C/5 % CO2 for 24 hours. The XF Assay Cartridge
was calibrated by adding XF calibrant for 18 hours in a
37 °C - CO2 free incubator. During the equilibration
period, the XF24 Analyzer was calibrated with a calibra-
tion plate using the standard XF calibration protocol. The
assay was initiated by replacing the growth medium from
each well with 600 μL of bicarbonate free/unbuffered
DMEM-based media (XF assay medium) containing
25 mM glucose and 1 mM sodium pyruvate, pre-warmed
at 37 °C. The cells were incubated at 37 °C for 1 hour in a
CO2 free incubator to allow media temperature and pH to
reach equilibrium before the first measurement. XF cell
Mito Stress Test Kit reagents were used to measure mito-
chondrial respiration. The drug injections ports of the XF
assay cartridge were loaded with the concentrated assay
reagents (13X stock) in the assay medium. After three
measurements of the baseline OCR, 10 μM oligomycin,
7 μM carbonyl cyanide 4-(trifluoromethoxy) phenylhydra-
zone (FCCP), 5 μM antimycin A and 5 μM rotenone were
sequentially added to each well. The changes in the OCR
measurements were analyzed and the data expressed as
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pmol of O2 per minute. The data were normalized by the
number of cells determined by Vybrant Green DNA stain
(Life Technologies, Invitrogen) at 1 μM final concentration.
Dye incorporation was measured using the INCUCYTE™
ZOOM live-cell imaging System (Essen Bioscience).
Transmission electron microscopy
1 x 106 cells were fixed in 2.5 % cacodylate buffered glutar-
aldehyde for a minimum of 2 hours. Cells were centrifuged
at 1800 x g for 10 minutes and the pellet resuspended in
2 mL sodium cacodylate buffer, pH 7.2. Through subse-
quent pelleting and resuspension, cells were post-fixed in
2 % osmium tetroxide for 2 hours, rinsed in water, and
dehydrated through graded ethanol up to absolute. A final
dehydration in pure acetone was followed by three changes
in Spurr’s resin (Canemco) and a final embedding at 65 °C.
Thin (80 nm) sections were cut using an Ultracut R ultra-
microtome (Leica) and stained with uranyl acetate, and
lead citrate. Grids were screened on a Hitachi 7100 trans-
mission EM and the images digitally captured. Images for
10 cells per sample were captured at low (3000X) and high
(30,000X) magnification. The number of mitochondria
per cell were counted manually using ImageJ software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 6.00 for Windows (GraphPad Software, San Diego,
CA) to determine p-value in repeated experiments, and the
type of test is indicated in the Figure legend. All results are
shown as mean +/- standard deviation. Unless otherwise
noted, all results were obtained through a minimum of
three independent experimental replications.
Results
We used fibroblasts derived from patients and healthy con-
trols for analysis. Patient 7 is compound heterozygous for
TRNT1 p.L166S and p.T154I mutations, whereas patient 8
is homozygous for the TRNT1 p.R190I mutation [2]. We
first examined by western blot analysis the levels of TRNT1
in patient-derived and control fibroblasts and confirmed a
decrease in the expression of TRNT1 in patient cells
(Fig. 1a). We next investigated whether the patient-derived
Fig. 1 Expression and localization of TRNT1 in patient-derived fibroblasts. a TRNT1 protein expression was analyzed in patient and control
fibroblasts by western blot analysis. Tubulin and Tom20 were used as loading controls. b Immunofluorescent imaging of TRNT1 in fibroblast cells.
Nuclei are identified by Hoechst stain and mitochondria is stained with an anti-Tom20 antibody (bar = 20 μm). c The expression of TRNT1 in the
cytoplasm and nucleus was calculated from images obtained on the Opera automatic confocal microscope. The ratio of the average intensity for
TRNT1 signal in the cytoplasm to nucleus was measured in approximately 90 cells per well. The mean ratio per well was averaged over 6 wells
and the standard deviation was calculated from the mean ratio values of the 6 wells
Liwak-Muir et al. Orphanet Journal of Rare Diseases  (2016) 11:79 Page 3 of 7
mutations alter the localization of TRNT1. We visualized
localization of endogenous TRNT1 by immunofluorescence
and counterstained cells with a Tom20 antibody (to identify
the mitochondria) and Hoechst stain (to identify nuclei)
(Fig. 1b). We observed that TRNT1 in patient-derived fibro-
blasts localizes to the nucleus, cytosol, and mitochondria
similar to control. Furthermore, although the expression
levels of TRNT1 are reduced in patient cells, the ratio of
cytoplasmic to nuclear TRNT1 did not differ significantly,
suggesting that the mutations in TRNT1 do not affect the
subcellular localization of TRNT1 (Fig. 1c). Mitochondria
undergo dynamic fusion and fission and the extent of the
fused network may have an effect on cell viability [7]. To de-
termine if there is a defect in fission or fusion, we stained
the cells with a Tom20 antibody and measured the length to
width ratio of the mitochondrial network (Additional file 1:
Figure S1; [8]). We did not observe a significant difference
in the mitochondrial network between patient-derived and
control fibroblasts (Fig. 1d). The cellular ultrastructure of
patient and control fibroblast cells was further examined by
electron microscopy (Fig. 2a and Additional file 1: Figure
S2) and we did not observe any gross morphological differ-
ences in mitochondria from patient or control cells. Fur-
thermore, we counted the number of mitochondria per cell
and found no significant difference between patients and
control (Fig. 2b). Next, to determine any changes in the
mitochondrial transmembrane potential in patient cells as
compared to control we treated cells with TMRE (to
Fig. 2 Mitochondria are not altered in patient-derived fibroblasts. a Electron microscopy images of control and patient-derived fibroblasts at 3000X and
30,000X. The red box identifies the area under 30,000X magnification. b The number of mitochondria was determined using ImageJ software by manual
counting from 10 cells each from control or patients from the EM images. c Immunofluorescence images of the mitochondrial membrane potential as
monitored by the incorporation of the TMRE dye and compared to the total mitochondrial stain as measured by MitoTracker. Nuclei are identified by
Hoechst stain. (bar = 50 μm) (d) The relative TMRE intensity was measured and compared to cells treated with the uncoupler CCCP
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monitor membrane potential) and with MitoTracker Green
(to stain all mitochondria regardless of potential) (Fig. 2c
and Additional file 1: Figure S3) and quantified the relative
TMRE fluorescence as compared to fluorescence with the
uncoupler CCCP (Fig. 2d). We determined that there is no
significant difference in mitochondrial membrane potential
in patient-derived fibroblasts when compared to control
cells.
Next, we examined mitochondrial respiration by micro-
oximetry to assess any differences in mitochondrial oxidative
phosphorylation (OXPHOS) in patient fibroblasts compared
to that of the controls (Fig. 3a). We observed a significant
difference in the overall basal and maximal oxygen con-
sumption rates (OCR; Fig. 3b) in patient cells when com-
pared to control. We therefore examined the expression
levels of some of the proteins of the OXPHOS complexes
by western blot analysis (Fig. 3c and Additional file 1: Figure
S4). We used an antibody cocktail that probes for
representative proteins of the OXPHOS complexes as these
proteins are known to be labile when the complex is not
properly assembled. Interestingly, we observed a decrease in
NDUFB8 (complex I), SDHB (complex II), and COX II
(complex IV) proteins. Since NDUFB8 and SDHB are
encoded in the nucleus and translated in the cytoplasm, we
performed 35S-methionine/cysteine incorporation assays in
patient-derived fibroblasts (Fig. 3d) to determine if global
translation defects could explain the loss in expression of
these proteins. Surprisingly, we observed that global transla-
tion is not impaired in fibroblasts with mutated TRNT1.
Discussion
We have recently described a novel form of congenital
sideroblastic anemia that is associated with B-cell im-
munodeficiency, periodic fevers and developmental delay
(SIFD) in which we identified mutations in TRNT1 and
demonstrated that these mutations are disease causing.
Fig. 3 Decreased oxygen consumption rates correlate with a loss in OXPHOS complex protein expressions. a Oxygen consumption rate (OCR) of patient
and control fibroblasts as measured by micro-oximetry analysis. b Basal and maximal OCR was calculated from repeated experiments (*p< 0.05, ***p< 0.0001;
Kruskal-Wallis test with a Dunn's multiple comparisons post test) (c) Western blot analysis of 5 OXPHOS proteins representing each of the complexes involved
in oxidative phosphorylation. d 35S-methionine incorporation assay to measure global cytoplasmic translation. Autoradiography represents the 35S signal from
newly synthesized proteins and Coomassie represents total protein loading
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We were interested in studying the mechanisms by
which mutated TRNT1 might cause disease. Since some
of the symptoms associated with SIFD appear to be re-
lated to metabolic syndrome, we were interested in de-
termining how the patient-derived TRNT1 mutations
affect mitochondrial biology, and we focused our studies
on mitochondrial processes in patient-derived fibro-
blasts. Interestingly, immunofluorescence analysis of
TRNT1 subcellular localization and electron microscopy
of cells showed no gross morphological differences be-
tween patient and control cells, and that the number of
mitochondria per cell and their structure are similar.
Our initial findings using micro-oximetry analysis dem-
onstrated that basal and maximal respiration are de-
creased in patient cells as compared to healthy control
cells. Furthermore, our western blot analyses further
suggest a defect in cellular respiration by demonstrating
a decrease in expression of some OXPHOS complex
subunits. Notably, at least two of the affected proteins
(NDUFB8 (complex I) and SDHB (complex II)) are
encoded in the nucleus, an observation which would be
consistent with the global role of TRNT1 in tRNA mat-
uration. However, we did not observe any defect in cyto-
plasmic translation, suggesting that the decrease in
abundance of these proteins might be due to complex
assembly, rather than protein synthesis. Because the
OXPHOS system is assembled from both nuclear- and
mitochondrial-encoded components, proper assembly of
these complexes is essential and, in fact mutations in
assembly factors are associated with human pathologies
[9]. We have also observed a specific decrease in the
abundance of the mitochondrial–encoded COX II (com-
plex IV) protein. We are currently conducting SILAC
experiments to identify the full spectrum of changes in
the abundance and stoichiometry of all OXPHOS com-
plexes as well as changes in the abundance of additional
mitochondrial proteins.
Sasarman et al. (2015) have recently described a defect
in mitochondrial tRNASer (AGY) CCA addition associ-
ated with TRNT1 mutation that leads to impairment of
mitochondrial translation and decreased abundance in 13
mitochondrial subunits of OXPHOS complexes, which is
congruent with our observation. In contrast to our obser-
vations, however, the changes observed by Sasarman et al
were restricted to muscle biopsies with minimal effect seen
in fibroblasts. It is possible that this difference is due to
distinct TRNT1 mutations found in patients. Indeed, both
patient 7 and patient 8 displayed both reduced TRNT1 ac-
tivity [2] and expression levels (Fig. 1), presumably leading
to more severe TRNT1 deficiency than that observed by
Sasarman et al. Of note, both patient 7 and patient 8 are de-
ceased suggesting that these mutations are on the more se-
vere end of the TRNT1 pathology spectrum. Recently,
hypomorphic mutations in TRNT1 were also found to cause
rare non-syndromic retinitis pigmentosa with erythrocytic
microcytosis [10]. The three patients in this study displayed
nyctalopia, microcytosis and anisocytosis, but were other-
wise healthy and lacking typical SIFD symptoms such as
developmental delay, deafness, ataxia, seizures or cardiac
disease. In contrast to our patient cohort, the mutations
found in these patients were located to the extreme C-
terminus or the N-terminal head-domain of TRNT1 and
could be considered to have a mild effect on TRNT1 func-
tion. Interestingly, however, morpholino-based modest re-
duction of TRNT1 levels in zebrafish model recapitulated
the vision-selective phenotype, whereas the more severe
knock-down also resulted in an eye and heart development
abnormalities, reduced touch response and erythrocyte
maturation, recapitulating some of the SIFD features. Fur-
thermore, TRNT1 morphants displayed reduced CCA-
incorporation efficiency similar to our patients. Unfortu-
nately this study did not assess the mitochondrial activity in
either patients or zebrafish model, Taken together these data
further support the notion that the clinical variability associ-
ated with SIFD may be linked to distinct mutations in
TRNT1 and expression levels of TRNT1 resulting in an im-
balance in cytoplasmic and mitochondrial protein synthesis
and the consequent effect on mitochondrial function.
Conclusions
We conclude that although patient fibroblast cells do not
appear to be defective in cellular morphology, TRNT1
localization, global translation, mitochondrial network archi-
tecture, or mitochondrial transmembrane potential, patient
cells harboring mutated TRNT1 are defective in their ability
to properly form OXPHOS complexes and consume oxy-
gen. This likely contributes to the observed mitochondrial
phenotypes associated with mutant TRNT1 and SIFD.
Additional file
Additional file 1: Figure S1. Immunofluorescent imaging of
mitochondrial network in fibroblast cells. (Left) Nuclei are identified by
Hoechst stain (red) and mitochondria are stained with an anti-Tom20 antibody
(green). Representative images are shown. (Right) The mitochondria segment
length was calculated as the pixel distance from between either the end of a
mitochondria or a branch point or the crossing over of another mitochondria
and is averaged for each cell using a custom Acapella script run in the
Columbus software. From 100 to 200 cells were measured per well and
averaged over 14 wells for three separate experiments. Figure S2. Electron
microscopy images of additional control fibroblasts. The red box identifies
the area enlarged on the right. Figure S3. Additional control fibroblasts for
membrane potential assessment. Shown are immunofluorescence images
of the mitochondrial membrane potential as monitored by the incorporation
of the TMRE dye (red) and compared to the total mitochondrial stain as
measured by MitoTracker (green). Nuclei are identified by Hoechst stain (blue).-
Figure S4. (A) Oxygen consumption rate (OCR) of three control fibroblasts as
measured by micro-oximetry analysis. (B) Densitometry of western blot analysis
of 5 OXPHOS proteins. The band intensities were determined using ImageJ
software. The intensity of each band is shown relative to total protein
(ns = not significant; * = p < 0.05; ** = p<0.01; student t-test). (PDF 2743 kb)
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